Tourmaline Bio, Inc.
TRML
$15.10
-$0.64-4.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.74% | -23.48% | 77.30% | 224.84% | 349.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.75% | 73.31% | 267.88% | 34.18% | 133.50% |
| Operating Income | -49.75% | -73.31% | -267.88% | -34.18% | -133.50% |
| Income Before Tax | -72.56% | -72.34% | -260.88% | -8.42% | -77.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.56% | -72.34% | -260.88% | -8.42% | -77.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.56% | -72.34% | -260.88% | -8.42% | -77.43% |
| EBIT | -49.75% | -73.31% | -267.88% | -34.18% | -133.50% |
| EBITDA | -49.76% | -73.38% | -268.22% | -34.18% | -133.55% |
| EPS Basic | -61.77% | -6.92% | 84.82% | 95.83% | 93.33% |
| Normalized Basic EPS | -61.74% | -38.08% | 84.82% | 95.83% | 93.32% |
| EPS Diluted | -61.77% | -6.92% | 84.82% | 95.83% | 93.33% |
| Normalized Diluted EPS | -61.74% | -38.08% | 84.82% | 95.83% | 93.32% |
| Average Basic Shares Outstanding | 6.69% | 61.19% | 2,277.03% | 2,498.38% | 2,558.06% |
| Average Diluted Shares Outstanding | 6.69% | 61.19% | 2,277.03% | 2,498.38% | 2,558.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |